ALPRAZOLAM
THERAPEUTICS
Class
- Neuroscience-based Nomenclature: GABA positive allosteric modulator (GABA-PAM) Benzodiazepine (anxiolytic)
ALPRAZOLAM commonly prescribed for
(Bold for FDA approved)
How ALPRAZOLAM works
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibits neuronal activity presumably in amygdala-centered fear circuits to provide therapeutic benefits in anxiety disorders
How long until ALPRAZOLAM works
• Some immediate relief with first dosing is common; can take several weeks with daily dosing for maximal therapeutic benefit
SIDE EFFECTS
Notable Side Effects
✽ Sedation, fatigue, depression ✽ Dizziness, ataxia, slurred speech, weakness ✽ Forgetfulness, confusion ✽ Hyperexcitability, nervousness
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
Life Threatening Side Effects
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
weight gain

unusual
sedation

not usual
What to do about ALPRAZOLAM side effects
• Wait
• Wait
• Wait
• Lower the dose
• Switch to alprazolam XR
• Take largest dose at bedtime to avoid sedative effects during the day
• Switch to another agent
• Administer flumazenil if side effects are severe or life-threatening
DOSING AND USE
usual dosage range
• Anxiety: alprazolam IR: 1–4 mg/day
• Panic: alprazolam IR: 5–6 mg/day
• Panic: alprazolam XR: 3–6 mg/day
Dosage Forms
• Alprazolam IR tablet 0.25 mg scored, 0.5 mg scored, 0.8 mg, 1 mg scored, 2 mg multiscored
• Alprazolam IR orally disintegrating tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Alprazolam XR (extended-release) tablet 0.5 mg, 1 mg, 2 mg, 3 mg
long term use
• Risk of dependence, particularly for treatment periods longer than 12 weeks and especially in patients with past or current polysubstance abuse
habit forming
• Alprazolam is a Schedule IV drug
• Patients may develop dependence and/or tolerance with long-term use
SPECIAL POPULATIONS
Renal Impairment
• Drug should be used with caution
Hepatic Impairment
• Should begin with lower starting dose (0.5–0.75 mg/day in 2 or 3 divided doses)
Cardiac Impairment
• Benzodiazepines have been used to treat anxiety associated with acute myocardial infarction
Elderly
• Should begin with lower starting dose (0.5–0.75 mg/day in 2 or 3 divided doses) and be monitored closely
Children and Adolescents
• Safety and efficacy not established but often used, especially short-term and at the lower end of the dosing scale
• Long-term effects of alprazolam in children/adolescents are unknown
• Should generally receive lower doses and be more closely monitored
Pregnancy
• Risk Category D [positive evidence of risk to human fetus; potential benefits may still justify its use during pregnancy]
• Possible increased risk of birth defects when benzodiazepines taken during pregnancy
• Because of the potential risks, alprazolam is not generally recommended as treatment for anxiety during pregnancy, especially during the first trimester
• Drug should be tapered if discontinued
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
• Seizures, even mild seizures, may cause harm to the embryo/fetus
Breast Feeding
• Some drug is found in mother’s breast milk ✽ Recommended either to discontinue drug or bottle feed
• Effects on infant have been observed and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera